1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

  • December 2016
  • 110 pages
  • ID: 3172450

Summary

Table of Contents

Search Inside

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

Summary
Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with sedentary lifestyles and obesity. As one of the most significant preventable causes of death worldwide, early diagnosis of the condition is crucial to improve health outcomes. Hypertension is the key risk factor for stroke; according to the National Stroke Association (NSA), two-thirds of patients who suffer a stroke have hypertension.

The anti-hypertensive therapeutics market is expected to grow significantly over the forecast period across the five Asia-Pacific (APAC) markets, from $19.1 Billion in 2015 to $27 Billion by 2022, at a compound annual growth rate (CAGR) of 5.1%. This growth is primarily attributed to the increasingly elderly population – where the prevalence rate of hypertension is at the highest – and increases in risk factors such as being overweight or obese, high daily sodium intake, low physical activity levels, urbanization, consumption of alcohol, smoking, and mental stress. In the five assessed APAC countries, the total population aged 65 and over was 1 Billion in 2015, and this is expected to grow at a CAGR of 3.32% to reach 1.2 Billion in 2022 (US Census Bureau, 2016).

The antihypertensive pipeline consists of 112 pipeline products, most of which are small molecules. Most of the pipeline products are at early stages of development, with Discovery and Preclinical products accounting for 55%. Phase I, II and III products account for 40%, and Pre-registration products account for 4%.

In the five assessed APAC regions, the total estimated prevalence population of hypertension was approximately 548 million in 2015. Of these, approximately 335 million (61.1%) were undiagnosed. Moreover, among the diagnosed patients, approximately 104.7 million (49.1%) were untreated, while 108.5 million (50.9%) were treated with drug therapy. The low diagnosis and treatment rates are primarily due to the lack of awareness of the condition among healthcare professionals, patients, and the public. The asymptomatic nature of the disease is another major factor limiting the diagnosis rate, and a lack of frequent blood pressure checks due to limited affordability and healthcare accessibility in countries such as India and China is another contributing factor.

Moreover, two major marketed products, Benicar/Olmetec (olmesartan medoxomil), and Rasilez (aliskiren), are expected to see their patents expire in Japan and Australia during the forecast period. The patent of Olmetec is expected to expire in Japan in 2016 and Australia in 2017, while the patent of Rasilez (aliskiren) is expected to expire in Australia in 2020. Increasing generic competition across the five APAC regions will restrict market growth during the forecast period.

The report “Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline” provides an introduction to anti-hypertensive, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology, disease staging and prognoses for patients.

In depth, it provides the following -
- Detailed analysis of the drugs currently marketed for anti-hypertensive (Cozaar, Benicar, Micardis, Diovan, Azilva, Norvasc, Rasilez, Tritace, Carvedilol, Prestalia, Exforge).
- Provides detailed analysis of the pipeline for anti-hypertensive, by stage of development, molecule type, program type, mechanism of action and molecular target.
- Detailed analysis of recent clinical trials in this indication, by enrollment, duration and failure rate. Promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
- Supplies forecasts for the anti-hypertensive markets, including epidemiology, treatment usage patterns, pricing and market size for the 2015–2022 period. The five APAC markets are covered, and data are presented at a country level.
- Detailed analysis of the key market drivers and barriers for the anti-hypertensive markets.
- Describes the major deals that have taken place in the global anti-hypertensive markets in recent years. This coverage analyzes licensing and co-development agreements, segmented by stage of development, year, molecule type, mechanism of action and value.

Scope
The Asia-Pacific antihypertensive market will be valued at $27 billion in 2022, growing from $19.1 billion in 2015 at a CAGR of 5.1%. Hypertension prevalence is a prominent contributor to market size in the assessed countries. The market is mostly dominated by generics, and there are only a few patented products.
- Will generics continue to dominate treatment?
- How do the elderly populations and their associated risk factors affect prevalence?
- What effect will the patent expirations of currently branded therapies have on market value?
The current anti-hypertensive therapeutics pipeline is weak, comprising 112 molecules in various stages of development, dominated by small molecules.
- Which molecular targets appear most frequently in the pipeline?
- Is there potential for the pipeline to address unmet needs within the anti-hypertensive market?
Analysis of clinical trials since 2006 identified that anti-hypertensive products have a high rate of attrition.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?
The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the high annual cost of therapy. Growth in market size is projected to vary considerably across the five assessed markets.
- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
- How could changes in risk factors such as aging population, metabolic disorders and high salt intake influence the market?
- Various drivers and barriers will influence the market over the forecast period.
- What are the barriers that limit the uptake of premium-priced therapeutics in the assessed countries?
- Which factors are most likely to drive the market in these countries?

Reasons to buy
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the anti-hypertensive market in terms of the dominant therapies, and their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the anti-hypertensive pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in hypertension clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Predict anti-hypertensive market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify commercial opportunities in the anti-hypertensive deals landscape by analyzing trends in licensing and co-development deals.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Nicolas helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026

Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026

  • $ 10995
  • Industry report
  • June 2018
  • by GlobalData

Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026SummaryDry Eye Syndrome (DES) is a multifactorial disease of the tears and ocular surface that causes ocular discomfort, visual disturbances, ...

Gene Therapy in Oncology

Gene Therapy in Oncology

  • $ 7995
  • Industry report
  • June 2018
  • by GlobalData

Gene Therapy in OncologySummaryGene therapy refers to any procedure that aims to treat or alleviate a disease by genetically modifying the cell of a patient. The material to be transferred may consist ...

Neuroblastoma - Market Insights, Epidemiology and Market Forecast-2027

Neuroblastoma - Market Insights, Epidemiology and Market Forecast-2027

  • $ 6250
  • Industry report
  • June 2018
  • by Delve Insight

DelveInsight’s ‘Neuroblastoma - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the ...


ref:plp2016

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on